"Designing Growth Strategies is in our DNA"

Non Small Cell Lung Cancer (NSCLC) Therapeutics Market Size, Share, Trends and Industry Analysis by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Cancer Type (Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma), and Regional Forecast 2019-2032

Last Updated: March 10, 2025 | Format: PDF | Report ID: FBI100484

 


To get information on various segments, share your queries with us

SEGMENTATION

 SEGMENTATION

 DETAILS

By Therapy

·    Targeted Therapy

    ·   Bevacizumab

    ·    Dabrafenib/Trametinib

    ·   Erlotinib Hydrochloride

    ·   Osimertinib  

    ·   Others

·    Immunotherapy

    ·    Durvalumab

    ·    Nivolumab

    ·     Atezolizumab

    ·    Pembrolizumab

·    Chemotherapy

By Distribution Channel

·    Hospital Pharmacies

·    Retail Pharmacies

·    Online Pharmacies

·    Others

By Cancer Type

·    Adenocarcinoma

·    Squamous cell carcinoma

·    Large cell carcinoma

By Geography

·    North America (the U.S., and Canada)

·    Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)

·    Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)

·    Latin America (Brazil, Mexico, and Rest of Latin America

·    Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)
Non-Small Cell Lung Cancer Therapeutics Market Size, Share and Global Industry Trend Forecast till 2032
  • REPORT UPDATE
    IN PROCESS
  • 2019-2032
    (In Process)
  • 2023
    (In Process)
Consulting Services
    How will you benefit from our consulting services ?